Cancer drug found to silence aging cells’ harmful signals

As the body ages, cells accumulate that have stopped dividing. That alone is not catastrophic, but these cells continuously release a mix of pro-inflammatory signalling proteins. This phenomenon, known as the SASP (senescence-associated secretory phenotype), contributes to tissue damage, chronic inflammation, and a range of age-related diseases.

Until now, researchers focused mainly on eliminating these senescent cells entirely. But there is an alternative strategy: switching off the harmful signalling function without destroying the cells themselves. This approach is called senomorphic therapy (suppressing the SASP without cell removal).

CDK4/6 inhibitors as senomorphic agents

The study, published in Nature Aging, identifies a specific molecular pathway: the cyclin D–CDK4–CDK6 signalling axis not only governs cell division but also drives the inflammatory secretome of senescent cells. CDK4/6 inhibitors are approved drugs used in certain breast cancers. The researchers suggest these same agents could be repurposed as senomorphic therapies in aging and in cancer-treatment-related decline.

Two independent research groups, Rajesh et al. and Wang et al., reached the same conclusion. That convergence strengthens the finding, though this remains early-stage research. Clinical applications are not yet proven and require further studies in humans.

Why this matters for longevity

Cancer therapy accelerates senescence in patients, contributing to fatigue, cognitive decline, and earlier functional deterioration after treatment. If CDK4/6 inhibitors can temper that secretome, they open a potential treatment route for these side effects. For longevity research, it is notable that existing, approved drugs appear to target an aging mechanism. Whether that translates to health gains in practice remains to be determined.

Read the original article